On the stock market since 1998, it operates in the world of health and science. It has 226 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly above the class average — a step short of the very top.
The price looks reasonable next to what the company earns.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Growth: Sales growth trails the sector average.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 29% below its peak. The market has trimmed its expectations for the company.
Sales run at $52.7M a year. A small number, but proof the product has real buyers.
There is $30.3M in the vault; even if every debt were paid off, $22.0M would remain.
Over the last 12 months, company executives reported 22 buys and 1 sell. Management buying with its own money is usually read as a good sign.
A loss of $6.6M against $52.7M in annual sales. And on top of that, sales fell from the year before.
The growth engine is running at low revs right now. Report-card grade: 14/100.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 3/10.
On our five-subject report card, PLX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PLX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.